WNT3A and glioblastoma: Collectively, our findings reveal that the oncogenic route between sICAM‐1 and WNT3A is important as cellular crosstalk is involved in the mesenchymal shift of GBM after radiation, suggesting that a targeted therapy of sICAM‐1 in combination with radiotherapy would be the beneficial therapeutic strategy of GBM treatment.